RecruitingPhase 2Drug trialA Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerThis study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.